title: Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain.
abstract: Emergence and spread of Neisseria gonorrhoeae resistant to extended spectrum cephalosporins is a major problem threatening treatment of gonorrhoea and is further highlighted by the recent report of a second ceftriaxone-resistant N. gonorrhoeae strain (F89) in Europe, initially observed in France and subsequently identified in Spain. N. gonorrhoeae antimicrobial resistance (AMR) surveillance has acquired new importance and molecular tools have the potential to enhance bacterial culture-based methods. In this study, we established a polymerase chain reaction (PCR) protocol for direct detection of the F89 strain. A key component of this screening protocol was the development of a hybridisation probe-based melting curve analysis assay (mosaic501-hybPCR) to detect the presence of an A501P substitution on the N. gonorrhoeae mosaic penicillin binding protein 2 (PBP2) sequence, an important characteristic of the F89 strain. The mosaic501-hybPCR was evaluated using plasmid-derived positive controls (n=3) and characterised gonococcal (n=33) and non-gonococcal (n=58) isolates. The protocol was then applied to 159 clinical specimens from Sydney, Australia, collected during the first half of the year 2012 that were N. gonorrhoeae PCR-positive. Overall, the results indicate that the PCR-based protocol is suitable for direct detection of the N. gonorrhoeae F89 strain in non-cultured clinical samples. It therefore provides an additional tool to aid investigations into the potential spread of F89 strain throughout Europe and elsewhere.
authors.affiliation: Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, The University of Queensland, Queensland, Australia.
authors.forename: N
authors.initials: N
authors.lastname: Goire
authors.forename: M M
authors.initials: MM
authors.lastname: Lahra
authors.forename: M
authors.initials: M
authors.lastname: Ohnishi
authors.forename: T
authors.initials: T
authors.lastname: Hogan
authors.forename: A E
authors.initials: AE
authors.lastname: Liminios
authors.forename: M D
authors.initials: MD
authors.lastname: Nissen
authors.forename: T P
authors.initials: TP
authors.lastname: Sloots
authors.forename: D M
authors.initials: DM
authors.lastname: Whiley
mesh_terms: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D005060:Europe; D006801:Humans; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D046915:Penicillin-Binding Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction
chemical_list: D000900:Anti-Bacterial Agents; D046915:Penicillin-Binding Proteins; D002443:Ceftriaxone